A leading pharma company has reported strong results for the December quarter. In the third quarter, the company’s revenue increased by 18 percent to Rs. 2.49 has been viewed on 1 crore. While EBITA jumped 35 percent to Rs. 724 crore was recorded. The net profit of the company increased by 14 percent to Rs. 283 crores were seen. Ebitda margin registered a growth of 29.1 percent. The Indian business revenue of the pharma company grew by 17 percent to Rs. 1,259 crores. This also includes revenue post integration of Curation Healthcare with the company. According to secondary data from AIOCD, Torrent Pharma reported a growth of 12 per cent during the quarter as compared to 12 per cent for IPM. The Company’s field force was further expanded and the MR strength increased to 5,300. It also includes curation divisions.

In the nine months to December in the financial year, the company’s revenue grew by 15 per cent to Rs. 3,728 crore was kept. The revenue of the company’s Brazil business grew by 36 percent to Rs. 248 crores. German trade revenue grew 1 percent to Rs. 241 crore was kept. Whereas in America the revenue increased by 24 percent to Rs. 29 remained at 1 crore. On a constant currency revenue basis, it grew 13 percent to $3.5 million. As of December 31, 2022, the Company had a majority of 48 ANDAs pending before the USFDA. When he got 3 temporary majors. An ANDA was filed during the quarter. While one ANDA was given Major. An ANDA was filed during the quarter. While one ANDA was given Major. An ANDA was filed during the quarter. While one ANDA was given Major.